文献速递造血干细胞移植与细胞治疗淋巴瘤

伊沙佐米降低慢性移植物抗宿主病风险:cGVHD生物标志物的识别

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.
PubMed 文献 · Blood Adv · 2025-01-01

该前瞻性随机试验纳入73例异基因造血干细胞移植患者,治疗组自+100天起每28天接受4 mg伊沙佐米(IXZ)。中位随访24个月,IXZ组与对照组1年及2年中重度cGVHD累积发生率分别为3.23% vs 30.2%(HR 0.089,P=0.02)和13% vs 43%(HR 0.23,P=0.01)。

要点

  • 伊沙佐米组2年中重度cGVHD累积发生率为13%,对照组为43%(HR 0.23,P=0.01)。
  • 2年cGVHD无复发生存估计值伊沙佐米组为81%,对照组为49%(HR 0.30)。
  • T细胞STAT3和p38磷酸化增加及+180天类别转换B细胞和循环浆细胞比例较高与中重度cGVHD风险显著升高相关。

核心结论

  • 伊沙佐米给药可降低中重度慢性移植物抗宿主病的风险。
  • 可通过流式细胞术识别生物学模式以预测cGVHD风险。

研究设计与样本

  • 前瞻性随机试验,纳入73例患者。
  • 治疗组自+100天起每28天接受4 mg伊沙佐米(IXZ)。
  • 中位随访24个月。
  • 试验注册号NCT03225417。

主要发现

  • 1年中重度cGVHD累积发生率IXZ组为3.23%,对照组为30.2%(HR 0.089,P=0.02)。
  • 2年中重度cGVHD累积发生率IXZ组为13%,对照组为43%(HR 0.23,P=0.01)。
  • 2年cGVHD无复发生存估计值IXZ组为81%,对照组为49%(HR 0.30)。
  • T细胞STAT3和p38磷酸化增加与中重度cGVHD风险显著升高相关。
  • +180天发生免疫球蛋白类别转换的B细胞比例较高及循环浆细胞比例较高与中重度cGVHD风险显著升高相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) is the leading cause of long-term morbidity and mortality after allogeneic hematopoietic stem cell transplantation. We hypothesize that it is possible to decrease its risk by manipulating the immune response in late phases of transplantation. We performed a prospective randomized trial including 73 patients. Patients in the treatment arm received 4 mg of ixazomib (IXZ) every 28 days from day +100. With a median follow-up of 24 months, the cumulative incidence of moderate/severe cGVHD in the IXZ vs control groups at 1 and 2 years were: 3.23% vs 30.2% (hazard ratio [HR], 0.089; P = .02) and 13% vs 43% (HR, 0.23; P = .01), respectively. Estimates for cGVHD and relapse-free survival at 2 years were 81% for IXZ and 49% for the control group (HR, 0.30). Increased STAT3 and p38 phosphorylation in T cells, and higher proportion of B cells that have undergone immunoglobulin isotype switching and circulating plasma cells on day +180 were associated with a significantly higher risk of developing moderate/severe cGVHD. The administration of IXZ decreases the risk of moderate/severe cGVHD. It is possible to identify biological patterns by flow cytometry to predict the risk of cGVHD. This trial was registered at www.clinicaltrials.gov as #NCT03225417.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Caballero-Velázquez T, Delgado Serrano J, López-Corral L, et al. Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers. Blood Adv. 2025. PMID: 40737543. doi:10.1182/bloodadvances.2025016284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。